PACAP 1-38 acetate 是一种垂体腺苷酸环化酶激活多肽 (PACAP) 类似物。它与 PACAP I 型受体 (IC50 = 4 nM) 和 PACAP II 型 VIP2 受体 (IC50 = 1 nM) 结合，但不与 PACAP II 型 VIP1 受体结合。

PACAP 1-38 acetate is a pituitary adenylate cyclase activating polypeptide (PACAP) analogue. PACAP 1-38 acetate binds to PACAP type I receptor(IC50 = 4 nM) and PACAP type II VIP2 receptor(IC50 = 1 nM) but not to PACAP type II, VIP1 receptor.

The ability of neuropeptides to modulate enteric smooth muscle proliferation was examined in primary explant cultures of rabbit gastric antrum and colon smooth muscle. Cell proliferation was determined by [3H]thymidine incorporation measurements and cell counting. PACAP 1-38 acetate concentration dependently (10(-10)M to 10(-6)M) inhibited the serum-induced [3H]thymidine incorporation [in colon, 55.6 +/- 9.3% of control with 10(-7)M PACAP 1-38 acetate] and inhibited increase in cell numbers in cultures derived from the colon but not in those from the antrum. Effects of PACAP 1-38 acetate were mimicked by forskolin (10(-7) to 10(-6) M) but not by 8-bromo-cGMP. Substance P, motilin, calcitonin gene-related peptide, and somatostatin had no effect[3].

The effect on total pulmonary resistance (R1) was examined for inhaled PACAP 1-38 acetate in anesthetized, ventilated guinea pigs. Two minutes after inhalation, PACAP 1-38 acetate (36 +/- 6%) inhibited the increase in R1 (% inhibition of histamine-induced R1 prior to inhalation) caused by histamine i.v., whereas the vehicle (-1 +/- 10%) did not. The inhaled peptides caused no sustained effects on heart rate or blood pressure. Infusion of PACAP 1-38 acetate i.v. dose-dependently inhibited the increase in R1 caused by inhaled histamine and by carbachol i.v.[4].

PACAP 1-38 acetate

H2O:30mg/mL,Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years